Free Trial

IPSEN (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?

IPSEN logo with Medical background

Key Points

  • IPSEN shares have crossed above their 200-day moving average, indicating a potential upward trend as they traded at a high of $30.97 with a last trading price of $30.05.
  • The company recently increased its dividend to $0.2896, representing a significant yield of 97.0%, up from its previous dividend of $0.23.
  • IPSEN is focused on biopharmaceuticals, with a diverse product pipeline covering oncology, neuroscience, and rare diseases, including several drugs in various stages of clinical trials.
  • Want stock alerts on IPSEN? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $29.63 and traded as high as $30.97. IPSEN shares last traded at $30.05, with a volume of 402 shares trading hands.

IPSEN Stock Down 0.1%

The company has a fifty day moving average price of $30.56 and a two-hundred day moving average price of $29.61.

IPSEN Increases Dividend

The company also recently disclosed a dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were paid a $0.2896 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a dividend yield of 97.0%. This is an increase from IPSEN's previous dividend of $0.23.

IPSEN Company Profile

(Get Free Report)

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Read More

Should You Invest $1,000 in IPSEN Right Now?

Before you consider IPSEN, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IPSEN wasn't on the list.

While IPSEN currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines